Ordering workflow
How clinics order compounded medications
Every compounded order resolves into one of two shapes, and the shape decides everything downstream. An order compounded for an identified individual patient is what 21 U.S.C. § 353a is written around, so a state-licensed 503A pharmacy can fill it. An order that names no patient falls outside that exemption entirely: it needs a facility registered with FDA as an outsourcing facility under section 503B, and it needs that facility to hold whatever credential the destination state requires on top of its federal registration.
What actually decides how your order works?
Whether the order names a patient. Everything else follows from that.
The word "order" is doing two jobs in this industry, and they are not variations on a theme — they are different transactions under different federal provisions, filled by different kinds of supplier, arriving with different labels. One is a prescription for an identified individual patient that happens to be for a compounded preparation. The other is a purchase of stock that no patient has been named for yet.
Georgia's rules make the distinction unusually visible. In the one channel where Georgia permits non-patient-specific supply, the rule directs that the recipient orders "in the same manner as ordering products from a wholesale pharmaceutical distributor... and not by using a prescription drug order." The rule is telling you, in its own words, that a stock order is not a prescription and does not travel as one.
Which pathway can fill each kind of order?
Federal law answers this cleanly, and it is the one part of the workflow that does not vary by state.
Section 353a exempts a compounded drug from three requirements of the Federal Food, Drug, and Cosmetic Act — current good manufacturing practice, labelling with adequate directions for use, and new drug approval — where the drug is "compounded for an identified individual patient based on the receipt of a valid prescription order." Remove the identified patient and the exemption does not attach.
Section 353b does not carry that condition. FDA states the consequence directly, contrasting the two pathways: outsourcing facilities are "subject to CGMP requirements, and they may distribute compounded drugs either pursuant to a patient-specific prescription or in response to an order from a health care provider, such as a hospital, that is not for an identified individual patient (e.g., for office stock)."
| Your order | Names a patient? | The pathway that can fill it | What the practice receives |
|---|---|---|---|
| Prescription for a named patient, delivered to the practice for administration | Yes | A state-licensed 503A pharmacy, or a facility registered with FDA as an outsourcing facility under section 503B | A dispensed preparation bearing that patient's name |
| Stock held in the practice for future patients | No | Only a facility registered with FDA as an outsourcing facility under section 503B, where the destination state allows the practice to hold it | Product labelled under 21 U.S.C. § 353b(a)(10), with no patient name |
Does a state permission change that answer?
Not at the federal layer, and several state rules say so in their own text.
North Carolina's office-use rule permits a pharmacy to supply compounded drug products to prescribers and then adds that such compounding for office use "shall comply with applicable federal law." Ohio's compounding rule directs a pharmacy to comply with 21 U.S.C. § 353a. New Jersey bars the practice for human use "except to the extent permitted by Federal law."
A rule phrased that way has not created a federal safe harbour — it has handed the question back to the federal provision, which conditions on the identified individual patient. So when a supplier cites a state rule containing that phrase, the rule text is only half the citation; the other half is which federal provision they say is satisfied, and how. Whether your own state permits your practice to hold stock at all is answered, with each state's rule text and citation, in the office-use compounding by state guide.
What has to be true before a first order can be placed?
The supplier has to be able to establish that you are lawfully allowed to receive what you are asking for, and in several states that duty is written into the supplier's own licence.
Arizona requires a nonresident outsourcing facility to "maintain a copy of the current permit or license of each person in Arizona that buys, receives, or disposes of" the drug, and the parallel nonresident-pharmacy rule requires the same copy to be producible within two business days. Louisiana binds distributors to "sell or distribute legend drugs or legend devices only to a person who is authorized, by law or regulation, to procure or possess legend drugs or legend devices."
So the credentialing step is not a supplier's administrative preference. It is the supplier discharging its own licence conditions, which is why it happens before the first order rather than alongside it. What gets checked, and by whom, is set out at prescriber credentialing: what pharmacies verify, and the sequence itself at opening an account with a compounding pharmacy.
What paperwork sits underneath a stock relationship?
In at least one of the states we have read, a written agreement between the pharmacy and the practitioner is a rule requirement rather than a formality.
Texas's office-use rules require a written agreement between the pharmacy and the practitioner. Georgia's veterinary channel goes further and specifies content: the agreement must include the practitioner's agreement that the preparation "may only be administered to the patient and may not be dispensed to the patient or sold to any other person or entity," subject to a narrow emergency exception, and the practitioner must chart the lot number and the beyond-use date.
Those are particular states' rules, not a national standard, and they attach to non-patient-specific supply rather than to ordinary prescriptions. But they are worth knowing before you are surprised by them, because they change what a supplier has to have on file before it can ship you anything.
How does the order actually reach the pharmacy?
By the route the order's own shape permits, which is a narrower question than it sounds.
A prescription for a named patient is a prescription, and it moves the way your practice's prescriptions already move. A stock order is not a prescription, has no patient to name, and therefore cannot travel as one — Georgia's rule text says exactly that. Arizona has also written a rule aimed at prescriptions arriving through platforms: from 5 September 2026, its rules bar filling copy prescriptions submitted "through a pharmacy platform or electronic system" without patient-specific clinical information.
The transmission plumbing itself — directories, routing networks, message standards — was not researched from primary sources and is not described anywhere on this site. What is answerable is which orders can move as prescriptions at all, and that is set out at EMR to pharmacy: how compounded prescriptions transmit.
What changes when your patients are in more than one state?
The destination state's law follows the shipment, and in several states it does so by express adoption rather than by inference.
New York binds a registered nonresident establishment to New York's own pharmacy provisions for anything delivered into New York. Colorado's rules provide that nonresident outlets registered in Colorado "may dispense compounded products and ship them into Colorado only pursuant to valid, patient-specific prescription orders." California requires a nonresident pharmacy compounding sterile products for shipment into the state to hold a sterile compounding pharmacy licence issued by its board, with an annual on-site inspection at the pharmacy's own expense.
The practical consequence for a multi-state practice is that "our pharmacy is licensed" is an incomplete answer — the question is which states it is licensed in. That is worked through at multi-state practice ordering: what changes per state.
Is FDA registration enough for an outsourcing facility to ship into your state?
No, and this is the most commonly misstated point in the whole workflow.
Section 353b is a federal exemption from federal law. It preempts nothing at the state level. Every state we checked requires the outsourcing facility to hold a state credential in addition to its FDA registration, and the credential is not always issued by the board of pharmacy: North Carolina's registration runs through the Commissioner of Agriculture, Texas's through its Department of State Health Services, California's and Florida's through their boards of pharmacy. Georgia's position on this specific question is unverified in our research and is marked as such rather than assumed.
A facility that satisfies section 353b in full and holds no credential in the destination state is not compliant — it is federally clean and state-exposed. Asking a prospective supplier which states it holds credentials in is a reasonable diligence question and a cheap one.
What arrives with the product?
Different labelling, depending on which pathway filled the order, and the difference is not a defect.
Product from a facility registered with FDA as an outsourcing facility arrives under the federal labelling requirements at section 353b(a)(10) and carries no patient name. That is correct for that pathway, not a violation. State office-use rules that impose their own legend generally bind pharmacies: Illinois requires the legend "For Office Use Only Not for Resale" on office-use containers supplied by a pharmacy, and Texas's office-use legend likewise attaches to a Texas-licensed pharmacy rather than to an outsourcing facility.
Arizona's current rule, in force through 4 September 2026, requires a two-legend label on human office-use product — "Not For Dispensing" and "For Office or Hospital Administration Only." From 5 September 2026 that human channel closes and Arizona's compounded office stock is available only to veterinarians.
What does the practice have to keep on its side?
State law, and it varies enough that the honest answer is to check yours rather than adopt anyone's default.
Among the states we have read in full, the retention periods that bind a practice rather than a pharmacy are genuinely different from each other. Texas requires a practitioner to "maintain a record of each acquisition and each disposal of a dangerous drug for two years," inspectable at all reasonable hours along with an inventory of stocks on hand. California requires a current inventory kept by every physician "who maintains a stock of dangerous drugs," preserved at least three years. New Jersey's controlled-substance records run two years or the professional licensing board's period, whichever is longer. Colorado, on the rules we read, attaches no retention period, labelling duty or reporting duty to the receiving practice at all.
Most of these bind the practice regardless of whether the source was a 503A pharmacy or a 503B outsourcing facility.
What does not vary by state?
Two things, and they are both federal.
The first is the identified-patient condition in section 353a, which is what the whole two-pathway structure hangs on. The second is that neither pathway produces an approved drug: both provisions work by exempting a preparation from the approval requirement, so no compounded preparation is approved by FDA, and no compounding facility is FDA-approved or FDA-licensed either. FDA's own words in a 2026 warning letter are that "the FD&C Act does not establish an 'FDA-approved' or 'FDA-licensed' designation for pharmacies or outsourcing facilities."
That matters operationally as well as legally. A supplier describing itself with either phrase is telling you something about its compliance posture before you have asked a single question about its licences.
How should an order be planned around dating?
Around what the date is evidence of, not around a number.
A 503A preparation carries a beyond-use date assigned under the compendial chapter its state has adopted — a conservative default keyed to dosage form, compounding environment and category. A facility registered under section 503B operates under current good manufacturing practice, in which an expiration date "shall be determined by appropriate stability testing." The kinds of evidence behind the two dates are different.
That difference is the honest one to plan against. This site publishes no day-counts for either: the compendial tables are paywalled and were not retrieved, and FDA's outsourcing-facility dating expectations were not examined. Any supplier quoting you a dating number should be able to say which regime and which document it comes from.
Where does this page stop?
At the two questions it deliberately does not answer.
It does not tell you whether your state permits your practice to hold non-patient-specific stock — that is the office-use compounding by state guide, which carries each state's rule text verbatim with its citation. And it does not compare the two pathways in the abstract; that is 503A pharmacies and 503B outsourcing facilities compared.
What it does answer is the question that comes before both: which of the two transactions you are actually trying to run, because that is what makes every other answer on this site apply to you or not. If the honest answer is "we are not sure yet," the comparison at office stock and patient-specific fulfilment compared is the one that resolves it.
If you want your state, your practice type and your preparation list mapped against the two routes before you order anything, you can apply for an account.